J. Parkinson

发表

What is the harm-benefit ratio of Cox-2 inhibitors?

I Persson, J Parkinson, L. Smeeth, 2008, International journal of epidemiology.

Medical Record Databases

S. Langan, A. Ogdie, K. Kostev, 2012 .

Using national registry data and record linkage to inform post-market surveillance of prosthetic aortic valve models over 15-years 2

Iain, A. Bryan, J. Dunning, 2016 .

The Clinical Practice Research Datalink: The New 54 Million Fully Integrated Research Data and Clinical Trial System

J. Parkinson, 2014 .

Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?

L. Smeeth, H. Leufkens, I. Persson, 2008, Pharmacoepidemiology and drug safety.

New approaches to drug safety: a pharmacovigilance tool kit

A. Breckenridge, J. Raine, L. Wise, 2009, Nature Reviews Drug Discovery.

Examples of Existing Automated Databases

S. Langan, A. Ogdie, R. Davis, 2013 .

National Registry Data and Record Linkage to Inform Postmarket Surveillance of Prosthetic Aortic Valve Models Over 15 Years

A. Bryan, I. Buchan, J. Dunning, 2017, JAMA internal medicine.

The General Practice Research Database: Now and the Future

T. Staa, J. Parkinson, Tjeerd van Staa, 2007 .

Response to: validation studies of the health improvement network (THIN) database for pharmacoepidemiology research by Lewis et al.

J. Parkinson, T. van Staa, 2008, Pharmacoepidemiology and drug safety.